NADA/N-ARACHIDONOYLDOPAMINE– endocannabinoid, CB1

 

Endocannabinoids and related fatty acid derivatives in pain modulation.                    (abst – 2002)

http://www.ncbi.nlm.nih.gov/pubmed/12505698

 

Characterisation of the vasorelaxant properties of the novel endocannabinoid N- arachidonoyl-dopamine (NADA).                                                                                (full – 2004)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574254/

 

 

 

 

 

 

 

 

TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N- arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat.           (abst – 2004)                                http://www.ncbi.nlm.nih.gov/pubmed/15245490

 

Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. (full – 2005)                                       http://www.jimmunol.org/content/175/6/3990.long

 

Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N- arachidonoyldopamine (NADA) in the rat isolated aorta. (abst – 2005)  http://www.ncbi.nlm.nih.gov/pubmed/15659311

 

Targeted lipidomics: fatty acid amides and pain modulation.                      (abst – 2005)

http://www.ncbi.nlm.nih.gov/pubmed/16099389

 

Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.                                                           (abst – 2007)  http://www.ncbi.nlm.nih.gov/pubmed/17459108

 

N-                            arachidonoyl dopamine is a possible factor of the rate of tentacle formation in freshwater hydra                  (abst – 2008)           http://www.ncbi.nlm.nih.gov/pubmed/18409382

 

The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine                                                    (full – 2009)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757501/

 

The endocannabinoid N-arachidonoyldopamine (NADA) exerts neuroprotective effects after excitotoxic neuronal damage via cannabinoid receptor 1 (CB(1)). (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22186081

 

The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells but not in hepatocytes

(abst – 2012)                        http://ajpgi.physiology.org/content/302/8/G873.abstract?rss=1

Share a link for